



Press release July 3, 2012

Genovis strengthens organization with international sales manager

Susanne Olauson has been appointed to be sales manager at Genovis. She joins us most recently from Redsense Medical, where she worked since 2007 in sales and marketing in the US, European and Australian markets.

Genovis is seeing a steady increase in orders and a strong interest in its recently launched products. To optimize these opportunities Susanne Olauson was hired as sales manager.

Susanne, 42, has a degree in business with an international background. Over the past fifteen years she has been active in life science, including both the pharmaceutical and medical device industries. Much of her work over the past five years has involved commercializing innovative Swedish medical devices internationally, from brand-building, product development, and sales to key customers.

"I'm really looking forward to being part of Genovis' expanding operations in new and existing markets. I look forward to applying my experience to help build Genovis' future," said Susanne Olauson

"As Genovis grows, we need talented, motivated employees. Susanne is goal and results-focused and her leadership style is a good fit with Genovis. Her experience of international sales to key customers is an important addition to Genovis in our current phase of expansion," says Sarah Fredriksson, CEO of Genovis

For more information, please contact:

Sarah Fredriksson, CEO, Genovis AB

T: +46 (0) 46-10 12 35

E: sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis develops and sells innovative technologies from two unique product portfolios. The first includes enzymes that facilitate development and quality control for applications such as antibody-based drugs. The products launched to date are aimed at customers who work with development of drugs, new diagnostic methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on design, production and characterization of nanostructures as contrast agents in medical imaging. The nanostructures and methods that Genovis focuses on can also be used as carriers of various substances in the development of new drug delivery methods. The projects are mainly in-house, but also include collaborations with research groups, including at Lund University.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00